Amarin Corp Plc (AMRN)

[ziploc_1]

The current situation for Amarin reminds me of the period after the FDA decision in 2013 when the FDA decided not to approve Vascepa for CVD until R-IT could be concluded...The potential that Amarin had with Vascepa did not mean much to the market as long as there was this fear of bankruptcy...At that time Amarin was in debt and had put up their patents as collateral...This is not the case today, but the fear of bankruptcy is hanging like a cloud over the share price...until this fear is lessened, the share price will continue to be in the gutter.

Management needs to continue to make it clear that Amarin is not in debt, has hundred's of millions in assets and is conserving capital(as they have recently stated)...and if they can break even or even show a little profit, that would go a long way to redirecting the market's focus to Vascepa's(orMD-2119's) potential stellar sales and help the share price.

It would also help if they could discuss their plans for MD-2119.
Perhaps they will do this at the AHA meeting in early November